In the last trading session, 72584.0 ProQR Therapeutics N.V (NASDAQ:PRQR) shares changed hands as the company’s beta touched 0.27. With the company’s per share price at $2.71 changed hands at $0.04 or 1.50% during last session, the market valuation stood at $279.68M. PRQR’s last price was a discount, traded about -70.48% off its 52-week high of $4.62. The share price had its 52-week low at $1.61, which suggests the last value was 40.59% up since then. When we look at ProQR Therapeutics N.V’s average trading volume, we note the 10-day average is 0.86 million shares, with the 3-month average coming to 1.54 million.
Analysts gave the ProQR Therapeutics N.V (PRQR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.33. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended PRQR as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. ProQR Therapeutics N.V’s EPS for the current quarter is expected to be -0.15.
ProQR Therapeutics N.V (NASDAQ:PRQR) trade information
Instantly PRQR was in green as seen at the end of in last trading. With action -9.18%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 34.85%, with the 5-day performance at -9.18% in the red. However, in the 30-day time frame, ProQR Therapeutics N.V (NASDAQ:PRQR) is -26.24% down. Looking at the short shares, we see there were 0.19 million shares sold at short interest cover period of 0.31 days.
The consensus price target for the stock as assigned by Wall Street analysts is 3.75, meaning bulls need an upside of 27.73% from its current market value. According to analyst projections, PRQR’s forecast low is 2 with 5 as the target high. To hit the forecast high, the stock’s price needs a -84.5% plunge from its current level, while the stock would need to tank 26.2% for it to hit the projected low.
ProQR Therapeutics N.V (PRQR) estimates and forecasts
Data shows that the ProQR Therapeutics N.V share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 61.82% over the past 6 months, a 18.42% in annual growth rate that is considerably higher than the industry average of 16.70%. Year-over-year growth is forecast to reach 119.83% up from the last financial year.
Consensus estimates given by 5 financial analysts project the company’s revenue in the current quarter to hit an average of 6.97M. 2 analysts are of the opinion that ProQR Therapeutics N.V’s revenue for the current quarter will be 8.99M. The company’s revenue for the corresponding quarters a year ago was 6.79M and 5.02M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 2.75%. The estimates for the next quarter sales put growth at 79.06%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 21.74%. The 2024 estimates are for ProQR Therapeutics N.V earnings to increase by 3.09%.
PRQR Dividends
ProQR Therapeutics N.V is expected to release its next quarterly earnings report in January.
ADAGE CAPITAL PARTNERS GP, L.L.C. holds the second largest percentage of outstanding shares, with 4.4446% or 3.63 million shares worth $6.02 million as of 2024-06-30.